Pulmonary Arterial Hypertension

Pulmonary Arterial Hypertension

Pulmonary Arterial Hypertension (PAH) is a rare, progressive disorder characterized by high blood pressure in the arteries that supply the lungs (the pulmonary arteries). It leads to the narrowing and stiffening of these arteries, making it harder for blood to flow through the lungs and putting extra strain on the heart. Symptoms include shortness of breath, fatigue, chest pain, and swelling in the legs and ankles. If left untreated, PAH can lead to heart failure. Increasing cases of PAH acts as primary driver for the growth of the market. For instance, as per the data of the World Health Organization (WHO), the global prevalence of PAH is estimated to be between 15 and 50 cases per million people. Further, as per the data of American Heart Association (AHA), in the United States, the incidence of PAH is about 2-5 cases per million adults annually.

The Pulmonary Arterial Hypertension Market is expected to grow at a steady rate of around 5% due to rising prevalence of PAH, advancements in therapeutics, and increased awareness and diagnosis. Further, continuous research and development in PAH therapies, including the introduction of novel drug classes and combination therapies, are driving market growth. Innovations such as prostacyclin analogs and endothelin receptor antagonists have significantly improved treatment efficacy.

• Based on the type, the market is segmented into Branded and Generics. In 2023, the branded sector held the biggest market share for pulmonary arterial hypertension. The greatest share of the branded segment can be attributed to market participants' significant investments, a robust pipeline, and an increasing number of product approvals. Additionally, during the projected period, an increasing number of product launches is anticipated to positively affect the segment's growth. For example, the FDA approved United Therapeutics Corporation's Tyvaso DPI powder in June 2022 for the treatment of pulmonary arterial hypertension.
• Based on the Drug Class, the market is segmented into Endothelin Receptor Antagonists (ERAs), PDE-5 Inhibitors, Prostacyclin and Prostacyclin Analogs, and SGC Stimulators. In 2023, prostacyclin and its analogs commanded the largest share of the global market and earnings. Prostacyclin is one of the best medications for treating PAH since it is a strong vasodilator. It is created by the Cyclooxygenase (COX) pathway from arachidonic acid, and endothelial cells in the pulmonary artery release it. By binding prostaglandin receptors and activating G protein and protein kinase, prostacyclin facilitates smooth muscle relaxation and vasodilation. A study conducted in October 2023 by experts from the American College of Cardiology found that oral prostacyclin receptor agonist selexipag has demonstrated encouraging outcomes in the treatment of PAH. The team is currently examining prostacyclin's effectiveness in treating pulmonary arterial hypertension.
• Based on the distribution channel, the market is segmented into Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy. In 2023, the market for PAH treatments was controlled by the hospital pharmacy segment. The senior population's rise, high hospitalization rates, and the severity of PAH are predicted to fuel the segment's expansion. Furthermore, improved reimbursement policies covering expensive treatment medicines in established and developing nations are anticipated to drive the segment's expansion.
• For a better understanding of the market adoption of Pulmonary Arterial Hypertension, the market is analyzed based on its worldwide presence in countries such as North America (U.S., Canada, and the Rest of North America), Europe (Germany, U.K., France, Spain, Italy, Rest of Europe), Asia-Pacific (China, Japan, India, Rest of Asia-Pacific), Rest of World. North America is dominating the market in the current scenario of 2023. This dominance can be attributed to several factors that drive the demand and development of PAH therapeutics in the region, such as high disposable income, advanced healthcare infrastructure, and rising awareness.
• Some of the major players operating in the market include United Therapeutics Corporation, Bayer AG, Gilead Sciences, Inc., Johnson & Johnson, Viatris Inc., GlaxoSmithKline, Sandoz Inc, Lupin Pharmaceuticals, Inc., Sun Pharmaceutical Industries, Inc., and Teva Pharmaceutical Industries Ltd.